Therapeutics

Vertex to Buy Crinetics for $10 Billion, Gaining Oral Endocrine Drugs

The acquisition delivers a marketed oral acromegaly therapy, with a late‑stage ACTH antagonist joining Vertex and signaling a push beyond its cystic fibrosis business.